The Moving Average Convergence Divergence (MACD) for DHR turned positive on October 14, 2026. Looking at past instances where DHR's MACD turned positive, the stock continued to rise in 29 of 47 cases over the following month. The odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on DHR as a result. In 50 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
Following a +1.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 177 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 111 of 199 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 11 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 38%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 64 cases where DHR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.115) is normal, around the industry mean (65.624). P/E Ratio (41.307) is within average values for comparable stocks, (2.414). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 20 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
IQV saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In 52 of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
The Moving Average Convergence Divergence (MACD) for IQV just turned positive on October 21, 2026. Looking at past instances where IQV's MACD turned positive, the stock continued to rise in 24 of 42 cases over the following month. The odds of a continued upward trend are 57%.
Following a +0.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where IQV advanced for three days, in 187 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 120 of 222 cases where IQV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IQV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
IQV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. IQV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 43 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.298) is normal, around the industry mean (65.624). P/E Ratio (33.695) is within average values for comparable stocks, (2.414). Projected Growth (PEG Ratio) (0.985) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.693) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IQV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
DHR | IQV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 22 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 77 | 43 | |
PRICE GROWTH RATING 1..100 | 20 | 6 | |
P/E GROWTH RATING 1..100 | 55 | 31 | |
SEASONALITY SCORE 1..100 | n/a | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (18) in the Medical Specialties industry is somewhat better than the same rating for IQV (74) in the Servicestothe Health Industry industry. This means that DHR’s stock grew somewhat faster than IQV’s over the last 12 months.
IQV's Profit vs Risk Rating (84) in the Servicestothe Health Industry industry is in the same range as DHR (100) in the Medical Specialties industry. This means that IQV’s stock grew similarly to DHR’s over the last 12 months.
IQV's SMR Rating (43) in the Servicestothe Health Industry industry is somewhat better than the same rating for DHR (77) in the Medical Specialties industry. This means that IQV’s stock grew somewhat faster than DHR’s over the last 12 months.
IQV's Price Growth Rating (6) in the Servicestothe Health Industry industry is in the same range as DHR (20) in the Medical Specialties industry. This means that IQV’s stock grew similarly to DHR’s over the last 12 months.
IQV's P/E Growth Rating (31) in the Servicestothe Health Industry industry is in the same range as DHR (55) in the Medical Specialties industry. This means that IQV’s stock grew similarly to DHR’s over the last 12 months.
| DHR | IQV | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 38% | N/A |
| Stochastic ODDS (%) | 1 day ago 58% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 56% | 1 day ago 68% |
| MACD ODDS (%) | 1 day ago 62% | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 57% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 71% |
| Advances ODDS (%) | 1 day ago 55% | 5 days ago 62% |
| Declines ODDS (%) | 8 days ago 59% | 9 days ago 64% |
| BollingerBands ODDS (%) | 1 day ago 57% | 1 day ago 57% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 54% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 2 FA rating(s) are green while IQV’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while IQV’s TA Score has 4 bullish TA indicator(s).
DHR (@Medical Specialties) experienced а +3.81% price change this week, while IQV (@Medical Specialties) price change was +2.90% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.18%. For the same industry, the average monthly price growth was -8.00%, and the average quarterly price growth was +45.24%.
DHR is expected to report earnings on Feb 03, 2027.
IQV is expected to report earnings on Oct 27, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +1.07% | ||
| TMO - DHR | 73% Closely correlated | +1.64% | ||
| RGEN - DHR | 68% Closely correlated | +1.83% | ||
| BIO - DHR | 64% Loosely correlated | +0.67% | ||
| A - DHR | 60% Loosely correlated | +1.67% | ||
| BRKR - DHR | 58% Loosely correlated | +1.11% | ||
More | ||||